Global Angina Pectoris Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 - 2025

  • ID: 4394933
  • Report
  • Region: Global
  • Acute Market Reports
1 of 4

FEATURED COMPANIES

  • Abbott Laboratories Inc.
  • Astra Zeneca plc
  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Forest Laboratories Inc.
  • Gilead Sciences, Inc.
  • MORE

The angina pectoris treatment market was valued at USD 8790.93 Mn in 2017, and is expected to reach USD 12,589.6 Mn by 2025, expanding at a CAGR of 5.2% from 2017 - 2025.

Market Insights

According to American College of Cardiology, Chronic angina affects over seven million North Americans and despite optimal pharmacological and interventional therapies, 32% of these patients remain symptomatic from coronary artery disease (CAD). The market experts suggest that, various approaches have included new pharmacologic antianginal agents, interventional approaches, and therapeutic angiogenesis for treatment of angina pectoris. The beta adrenergic blockers are the first line drugs and the largest drug class segment in angina pectoris treatment market. The major factors assisting growth of beta adrenergic blockers are the efficiency, fast onset of action, accessibility to patients and high patient compliance. A few drugs in phase III of clinical trials are observed as the most potential molecules in the angina pectoris treatment. These potential molecules are such as Dantonic/T89 (Tasly Pharmaceuticals, Inc.), Bococizumab (Pfizer, Inc.), and Alirocumab (Sanofi SA, Regeneron Pharmaceuticals). North America angina pectoris treatment market is the largest market globally due to factors such as Rising prevalence of angina pectoris, obesity in young population, sedentary lifestyle, and rising awareness related to early diagnosis of angina pectoris.

Pipeline Analysis

The phase III drugs included in the pipeline analysis are Dantonic/T89 (Tasly Pharmaceuticals, Inc.), RANCAD (TSH Biopharm Corporation Limited), Cilostazol (Korea Otsuka Pharmaceutical Co.,Ltd.), Bococizumab (Pfizer, Inc.), Ticagrelor (J.M. ten Berg/ Astra Zeneca plc), Auto-CD34+ cells (Baxalta US Inc.) and Alirocumab (Sanofi SA, Regeneron Pharmaceuticals). Dantonic /T89 is observed as the most potential drug molecule in angina pectoris treatment in the near future. According to Tasly Pharmaceuticals, Inc. the study completion of phase III trial for Dantonic would be by December 2016. According to U.S. National Institutes of Health, Dantonic (T89) is a botanical drug that comprises extracts of Danshen (Radix Salviae Miltiorrhizae) and Sanqi (Radix Notoginseng) with borneol in a capsule form. The drug is currently approved in 26 countries outside the USA for the treatment and prevention of chronic stable angina pectoris and other cardiovascular disease related conditions. This pivotal confirmative Phase III clinical trial is to confirm the efficacy and safety of the drug at 150mg and 225mg doses in the prevention and treatment of angina pectoris in patients with Chronic Stable Angina. Thus, according to its exceptional results projected in phase II suggest that Dantonic would be the most potential pipeline drug for angina pectoris treatement.

Key Market Movements:

  • Rising prevalence of angina pectoris due to sedentary lifestyle and obesity in young generation
  • High demand for target specific and tailored drugs for angina pectoris treatment
  • In developing countries from Asia Pacific and Latin America the awareness related to cardiovascular diseases in increasing
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abbott Laboratories Inc.
  • Astra Zeneca plc
  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Forest Laboratories Inc.
  • Gilead Sciences, Inc.
  • MORE
Chapter 1 Preface
1.1 Report Description
1.1.1 Study Purpose
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Methodology

Chapter 2 Executive Summary
2.1 Global Angina Pectoris Treatment Market Portaiture
2.2 Global Angina Pectoris Treament Market, by Drug Class, 2017 (USD Mn)
2.3 Relativity Analysis: Global Angina Pectoris Treatment Market, by Geography, 2017 & 2025 (USD Mn)

Chapter 3 Angina Pectoris Treatment Market: Market Dynamics and Outlook
3.1 Angina Pectoris Treatment Market Overview
3.2 Market Inclination Insights
3.3 Market Dynamics
3.3.1 Drivers
3.3.2 Challenges
3.3.3 Opportunities
3.4 Attractive Investment Proposition
3.5 Competitive Analysis
3.5.1 Market Share Analysis: Global Angina Pectoris Treatment Market, 2017 (Value %)

Chapter 4 Global Angina Pectoris Treatment Market, By Drug Class
4.1 Preface
4.2 Antiplatelet agents
4.3 Beta-adrenergic blocking agents
4.4 Calcium channel blockers
4.5 Short & Long - acting Nitroglycerines
4.6 Angiotensin-converting enzyme inhibitors
4.7 Anti-ischemic agents
4.8 Pipeline Analysis
4.8.1 Projected sales of Phase III Drugs estimated till 2025 (US$ Mn)
4.8.1.1 Dantonic/T89
4.8.1.2 RANCAD
4.8.1.3 Cilostazol
4.8.1.4 Bococizumab
4.8.1.5 Ticagrelor
4.8.1.6 Auto-CD34+ cells
4.8.1.7 Alirocumab
4.8.2 Tabular Representation of Phase II and I Drugs

Chapter 5 Global Angina Pectoris Treatment Market, By Geography
5.1 Preface
5.2 North America
5.2.1 U.S
5.2.2 Canada
5.3 Europe
5.3.1 U.K
5.3.2 Germany
5.3.3 Rest of Europe
5.4 Asia Pacific
5.4.1 China
5.4.2 Japan
5.4.3 Rest of Asia Pacific
5.5 Rest of the World (RoW)
5.5.1 Latin America
5.5.2 Middle East and Africa

Chapter 6 Company Profiles
6.1 Abbott Laboratories Inc.
6.1.1 Business Description
6.1.2 Financial Health and Budget Allocation
6.1.3 Product Portfolio
6.1.4 News Coverage
6.2 Astra Zeneca plc
6.2.1 Business Description
6.2.2 Financial Health and Budget Allocation
6.2.3 Product Portfolio
6.2.4 News Coverage
6.3 Bayer AG
6.3.1 Business Description
6.3.2 Financial Health and Budget Allocation
6.3.3 Product Portfolio
6.3.4 News Coverage
6.4 Bristol-Myers Squibb Company
6.4.1 Business Description
6.4.2 Financial Health and Budget Allocation
6.4.3 Product Portfolio
6.4.4 News Coverage
6.5 F. Hoffmann-La Roche Ltd.
6.5.1 Business Description
6.5.2 Financial Health and Budget Allocation
6.5.3 Product Portfolio
6.5.4 News Coverage
6.6 Forest Laboratories Inc.
6.6.1 Business Description
6.6.2 Financial Health and Budget Allocation
6.6.3 Product portfolio
6.6.4 News Coverage
6.7 Gilead Sciences, Inc.
6.7.1 Business Description
6.7.2 Financial Health and Budget Allocation
6.7.3 Product Portfolio
6.7.4 News Coverage
6.8 GlaxoSmithKline plc
6.8.1 Business Description
6.8.2 Financial Health and Budget Allocation
6.8.3 Product Portfolio
6.8.4 News Coverage
.9 Novartis AG
6.9.1 Business Description
6.9.2 Financial Health and Budget Allocation
6.9.3 Product Portfolio
6.9.4 News Coverage
6.10 Pfizer Inc.
6.10.1 Business Description
6.10.2 Financial Health and Budget Allocation
6.10.3 Product Portfolio
6.10.4 News Coverage
6.11 Sanofi SA
6.10.1 Business Description
6.10.2 Financial Health and Budget Allocation
6.10.3 Product Portfolio
6.10.4 News Coverage

List of Figures
Fig. 1 Global Angina Pectoris Treatment Market, by Drug Class, 2017 (USD Mn)
Fig. 2 Relativity Analysis: Global Angina Pectoris Treatment Market, by Geography, 2017 & 2022 (USD Mn)
Fig. 3 Attractive Investment Proposition, Global Angina Pectoris Treatment Market, 2017
Fig. 4 Market Share Analysis: Global Angina Pectoris Treatment Market, 2017 (Value %)
Fig. 5 Global Antiplatelet agents Market for Angina Pectoris Treatment, 2017 - 2025 (USD Mn)
Fig. 6 Global Beta-adrenergic Blocking Agents Market for Angina Pectoris Treatment, 20137- 2022 (USD Mn)
Fig. 7 Global Calcium Channel Blockers Market for Angina Pectoris Treatment, 2013 -2022 (USD Mn)
Fig. 8 Global Short & Long - acting Nitroglycerines Market for Angina Pectoris Treatment, 2017 - 2025 (USD Mn)
Fig. 9 Global Angiotensin-Converting Enzyme Inhibitors Market for Angina Pectoris Treatment, 2017 - 2025 (USD Mn)
Fig. 10 Global Anti-ischemic agents Market for Angina Pectoris Treatment, 2017 - 2025 (USD Mn)
Fig 11 Pipeline Analysis: Global Dantonic/T89 Market for Angina Pectoris Treatment, Upto 2022 (USD Mn)
Fig 12 Pipeline Analysis: Global RANCAD Market for Angina Pectoris Treatment, Upto 2022 (USD Mn)
Fig 13 Pipeline Analysis: Global Cilostazol Market for Angina Pectoris Treatment, Upto 2022 (USD Mn)
Fig 14 Pipeline Analysis: Global Bococizumab Market for Angina Pectoris Treatment, Upto 2022 (USD Mn)
Fig 15 Pipeline Analysis: Global Ticagrelor Market for Angina Pectoris Treatment, Upto 2022 (USD Mn)
Fig 16 Pipeline Analysis: Global Auto-CD34+ cells Market for Angina Pectoris Treatment, Upto 2022 (USD Mn)
Fig 17 Pipeline Analysis: Global Alirocumab Market for Angina Pectoris Treatment, Upto 2022 (USD Mn)
Fig. 18 Global U.S. Angina Pectoris Treatment Market Revenue, 2017 - 2025 (USD Mn)
Fig. 19 Global Canada Angina Pectoris Treatment Market Revenue, 2017 - 2025 (USD Mn)
Fig. 20 Global U.K Angina Pectoris Treatment Market Revenue, 2017 - 2025 (USD Mn)
Fig. 21 Global Germany Angina Pectoris Treatment Market Revenue, 2017 - 2025 (USD Mn)
Fig. 22 Global Rest of Europe Angina Pectoris Treatment Market Revenue, 2017 - 2025 (USD Mn)
Fig. 23 Global China Angina Pectoris Treatment Market Revenue, 2017 - 2025 (USD Mn)
Fig. 24 Global Japan Angina Pectoris Treatment Market Revenue, 2017 - 2025 (USD Mn)
Fig. 25 Global Rest of Asia Pacific Angina Pectoris Treatment Market Revenue, 2017 - 2025 (USD Mn)
Fig. 26 Global Latin America Angina Pectoris Treatment Market Revenue, 2017 - 2025 (USD Mn)
Fig. 27 Global Middle East and Africa Angina Pectoris Treatment Market Revenue, 2017 - 2025 (USD Mn)

List of Tables
Table 1 Global Angina Pectoris Treatment Market Revenue, by Drug Class, 2017 - 2025 (USD Mn)
Table 2 Global Angina Pectoris Treatment Marrket Revenue, by Geography, 2017 - 2025 (USD Mn)
Table 3 North America Angina Pectoris Treatment Market Revenue, by Country, 2017 - 2025 (USD Mn)
Table 4 Europe Angina Pectoris Treatment Market Revenue, by Country, 2017 - 2025 (USD Mn)
Table 5 Asia - Pacific Angina Pectoris Treatment Market Revenue, by Country, 2017 - 2025 (USD Mn)
Table 8 Rest of the World Angina Pectoris Treatment Market Revenue, by Region, 2017 - 2025 (USD Mn)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Abbott Laboratories Inc.
  • Astra Zeneca plc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Forest Laboratories Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll